Cilta-Cel Outcomes in R/R Multiple Myeloma: Omar Castaneda Puglianini, MD

Video

The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omar Castaneda Puglianini, MD, hematology and medical oncologist, Moffitt Cancer Center, to learn more about findings from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) evaluating ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma.

Investigators found that the overall response rate (ORR) was 97.9%. With longer follow-up, responses to the CAR T-cell therapy deepened. Castaneda Puglianini noted that the stringent complete response (sCR) rate increased from 67% at a median follow-up of 8 to 9 months, to 80.4% at 18 months.

The median duration of response with the agent was 21.8 months, and the median progression-free survival (PFS) was 22.8 months, Castaneda Puglianini adds. Notably, for patients who achieved a sCR, the median PFS was not reached. Response rates were also comparable across patient subgroups, including those who received previous lines of therapy and extramedullary disease. Overall, the efficacy demonstrated by cilta-cel on this study was impressive, Castaneda Puglianini concludes.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.